

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Material

Table of Contents

Supplemental Table 1. Kappa and percent agreement for app functionality (present or absent) as assessed by patient and nephrologist reviewers.

Supplemental Figure 1. Correlation of evaluations between (A) nephrologists and patients, and (B) consumers and patients, and (C) app store popularity and patients.

Supplemental Figure 2. Correlation of usability as assessed by patients and overall patient recommendation.


Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Table 1. Kappa and percent agreement for app functionality (present or absent) as assessed by patient and nephrologist reviewers. Note: * denotes that kappa was unable to be calculated.

| App Functionality | Kappa | % agreement |
|--|--------------|--------------------|
| <i>Educating patients</i> | | |
| Chronic kidney disease | 0.54 | 0.79 |
| Hemodialysis | 0.34 | 0.82 |
| Peritoneal dialysis | 0.34 | 0.82 |
| Kidney transplant | 0.84 | 0.96 |
| Conservative/palliative management of end stage kidney disease | -0.06 | 0.82 |
| Nephrotoxins (e.g. non-steroidals) | 0.26 | 0.86 |
| Drug-drug interactions for transplant meds | | 0.96 |
| Diet optimal for chronic kidney disease | 0.52 | 0.79 |
| Diet optimal for dialysis patients | 0.29 | 0.86 |
| Diet optimal for transplant patients | * | 0.93 |
| Fluid restriction | -0.06 | 0.79 |
| Hypertension | 0.27 | 0.79 |
| Diabetes and/or glucose control | 0.16 | 0.71 |
| Hyperkalemia | -0.08 | 0.86 |
| Hyperphosphatemia and/or secondary hyperparathyroidism | -0.08 | 0.86 |
| Hyponatremia | -0.05 | 0.89 |
| Anemia related to kidney disease | -0.09 | 0.82 |
| Parathyroidectomy | -0.05 | 0.89 |
| Heart disease | 0.47 | 0.93 |
| <i>Reminding patients</i> | | |
| Reminding patients to take medications | 0.47 | 0.93 |
| Reminding patients about follow-up appointments | * | 0.96 |
| Reminding patients to track symptoms | * | 1.00 |
| <i>Tracking aspects of chronic kidney disease</i> | | |
| Tracking creatinine or GFR over time | 1.00 | 1.00 |
| Tracking proteinuria over time | 1.00 | 1.00 |
| Tracking blood pressure over time | 1.00 | 1.00 |
| Tracking glucose over time | * | 0.96 |
| Tracking daily fluid intake | -0.05 | 0.89 |
| Tracking weight over time | 1.00 | 1.00 |
| Tracking anemia medication usage | * | 0.93 |
| Tracking levels of immunosuppression (e.g. tacrolimus trough) | * | 0.96 |
| Keeping a food diary | 0.52 | 0.89 |
| Keeping an up-to-date list of general medications | 0.52 | 0.89 |
| Keeping an up-to-date list of dialysis-related medications | 0.52 | 0.89 |
| Keeping an up-to-date list of transplant medications | 0.47 | 0.93 |
| <i>Guiding patients</i> | | |
| Determining of kidney disease severity (stage or eGFR) | 0.34 | 0.89 |
| Calculating BMI | -0.04 | 0.93 |

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 1. Correlation of evaluations between (A) nephrologists and patients, and (B) consumers and patients, and (C) app store popularity and patients. Note: the points have been slightly shifted randomly to minimize overlap.



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 2. Correlation of usability as assessed by patients and overall patient recommendation. Note: the points have been slightly shifted randomly to minimize overlap.

